@article{a655ab0d40e14f9ea45372382a9bb734,
title = "The genetic architecture of pediatric cardiomyopathy",
abstract = "To understand the genetic contribution to primary pediatric cardiomyopathy, we performed exome sequencing in a large cohort of 528 children with cardiomyopathy. Using clinical interpretation guidelines and targeting genes implicated in cardiomyopathy, we identified a genetic cause in 32% of affected individuals. Cardiomyopathy sub-phenotypes differed by ancestry, age at diagnosis, and family history. Infants < 1 year were less likely to have a molecular diagnosis (p < 0.001). Using a discovery set of 1,703 candidate genes and informatic tools, we identified rare and damaging variants in 56% of affected individuals. We see an excess burden of damaging variants in affected individuals as compared to two independent control sets, 1000 Genomes Project (p < 0.001) and SPARK parental controls (p < 1 × 10−16). Cardiomyopathy variant burden remained enriched when stratified by ancestry, variant type, and sub-phenotype, emphasizing the importance of understanding the contribution of these factors to genetic architecture. Enrichment in this discovery candidate gene set suggests multigenic mechanisms underlie sub-phenotype-specific causes and presentations of cardiomyopathy. These results identify important information about the genetic architecture of pediatric cardiomyopathy and support recommendations for clinical genetic testing in children while illustrating differences in genetic architecture by age, ancestry, and sub-phenotype and providing rationale for larger studies to investigate multigenic contributions.",
keywords = "ancestry, bioinformatics, clinical interpretation, exome, heart, infant, molecular diagnosis, variant",
author = "{Pediatric Cardiomyopathy Registry Study Group} and Ware, {Stephanie M.} and Surbhi Bhatnagar and Dexheimer, {Phillip J.} and Wilkinson, {James D.} and Arthi Sridhar and Xiao Fan and Yufeng Shen and Muhammad Tariq and Schubert, {Jeffrey A.} and Colan, {Steven D.} and Ling Shi and Canter, {Charles E.} and Hsu, {Daphne T.} and Neha Bansal and Webber, {Steven A.} and Everitt, {Melanie D.} and Kantor, {Paul F.} and Rossano, {Joseph W.} and Elfriede Pahl and Paolo Rusconi and Lee, {Teresa M.} and Towbin, {Jeffrey A.} and Lal, {Ashwin K.} and Chung, {Wendy K.} and Miller, {Erin M.} and Bruce Aronow and Martin, {Lisa J.} and Lipshultz, {Steven E.}",
note = "Funding Information: We thank the children and their families in the cardiomyopathy genetic study and SPARK for their participation. We also thank the Children's Cardiomyopathy Foundation for their ongoing support of the Pediatric Cardiomyopathy Registry's research efforts. The Pediatric Cardiomyopathy Registry is supported by grants to S.E.L. from the National Heart, Lung, and Blood Institute (HL53392, HL111459, and HL109090), in part from the National Institutes of Health (HL139968, HL137558, and CA211996), and the Children's Cardiomyopathy Foundation (Tenafly, New Jersey). SPARK is funded by the Simons Foundation as part of SFARI. S.M.W. is also supported for this work by an American Heart Association Established Investigator Award (13EIA13460001) and funding from the Indiana University School of Medicine Strategic Research Initiative and Physician Scientist Initiative. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI, NIH, or Children's Cardiomyopathy Foundation. J.W.R. is a consultant for Amgen, Bayer, Novartis, and Abiomed. W.K.C. is on the scientific advisory board for the Regeneron Genetics Center. S.E.L. is a consultant for Tenaya Therapeutics and Bayer and on an advisory board for Myokardia. Funding Information: We thank the children and their families in the cardiomyopathy genetic study and SPARK for their participation. We also thank the Children{\textquoteright}s Cardiomyopathy Foundation for their ongoing support of the Pediatric Cardiomyopathy Registry{\textquoteright}s research efforts. The Pediatric Cardiomyopathy Registry is supported by grants to S.E.L. from the National Heart, Lung, and Blood Institute ( HL53392 , HL111459 , and HL109090 ), in part from the National Institutes of Health ( HL139968 , HL137558 , and CA211996 ), and the Children's Cardiomyopathy Foundation (Tenafly, New Jersey). SPARK is funded by the Simons Foundation as part of SFARI. S.M.W. is also supported for this work by an American Heart Association Established Investigator Award ( 13EIA13460001 ) and funding from the Indiana University School of Medicine Strategic Research Initiative and Physician Scientist Initiative. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI, NIH, or Children{\textquoteright}s Cardiomyopathy Foundation. Publisher Copyright: {\textcopyright} 2021 American Society of Human Genetics",
year = "2022",
month = feb,
day = "3",
doi = "10.1016/j.ajhg.2021.12.006",
language = "English (US)",
volume = "109",
pages = "282--298",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "2",
}